Recipient NameChristopher K. Currin, R.Ph.
- RX South DBA RX3 Compounding Pharmacy LLC
12230 Iron Bridge Rd.
Chester, VA 23831-1534
- Issuing Office:
- Center for Drug Evaluation and Research
10 Waterview Blvd.
Parsippany, NJ 07054
- (973) 331-4900
Dear Mr. Currin:
The U.S. Food and Drug Administration (FDA) has completed an evaluation of your firm’s corrective actions in response to our warning letter dated October 23, 2014. Based on our evaluation, it appears that you have adequately addressed the violations contained in this warning letter.
You are expected to take all necessary steps to ensure compliance with the Federal Food, Drug, and Cosmetic Act and FDA’s implementing regulations. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.
Acting Program Division Director/District Director
Office of Manufacturing Quality Operations
Division I/New Jersey District